Studies luspatercept in adults with transfusion-dependent beta-thalassemia
Looks at luspatercept use in adults with beta-thalassemia who need regular blood transfusions.
Plain-language title generated from the registry record
Registry title: A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
Key facts
- Where
- Al Jahra, Andalusia, and Kuwait City, KuwaitSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with transfusion-dependent beta-thalassemia in the Middle East who started luspatercept in the last 12 months and are still on it.
- Age
- At least 18 years old when luspatercept treatment started.
- Sex
- Men and women can join.
- Disease stage
- Documented transfusion-dependent β-thalassemia (TDT).
- Earlier treatment
- Must have started luspatercept as described in the product's Summary of Product Characteristics no longer than 12 months before signing consent, and treatment must be ongoing.
Main reasons for not taking part
- Has any contraindication to luspatercept listed in the locally approved SmPC
- Is receiving or plans to receive an investigational drug, device or intervention
- Received an investigational product within 1 month or 5 half-lives (whichever is longer) before starting luspatercept
- Is pregnant, breastfeeding or planning a pregnancy during the study
- Has not signed informed consent
Read by machine on 9 November 2026.
Where in Kuwait
- Al JahraHospital not named in the registryNot yet recruiting
- AndalusiaHospital not named in the registryNot yet recruiting
- Kuwait CityHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07215975
- Record updated
- 19 August 2026
- Original description
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle EastRead full original descriptionShow less
REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East
Inclusion: Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment; Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT); Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing; Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study; Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study.
Exclusion: Participants who are currently receiving or are planned to receive treatment with any investigational drug/device/intervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation; Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC; Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period; Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.